Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paeoniflorin is a monoterpenoid glycoside and the principal bioactive compound found in the roots of Paeonia species, such as Paeonia lactiflora and Paeonia suffruticosa. It has been used in traditional Chinese medicine for over 2,000 years. Pharmacologically, paeoniflorin exhibits a broad spectrum of activities including anti-inflammatory, antioxidant, immunomodulatory, hepatoprotective, neuroprotective, antiplatelet, hypoglycemic (antidiabetic), antifibrotic, and cardiovascular protective effects[3][5][10]. Its mechanisms involve modulation of multiple signaling pathways such as TLR4-NF-κB (anti-inflammatory), PI3K/Akt/Nrf2 (antioxidant), JAK2/STAT6 (fibrosis inhibition), regulation of glucose metabolism via enhanced insulin sensitivity and secretion[3], inhibition of hepatic stellate cell activation[5], and protection against ischemia-reperfusion injury in neural tissue[7]. Preclinical studies suggest low toxicity with favorable safety profiles. It is under investigation for diabetes management and liver diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paeoniflorin.